United TherapeuticsUTHR
Recorded

United Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaSMID Biotech and Spec Pharma Analyst

All right, great. Thanks, everybody, for joining. My name is Ash Verma. I cover SMID Biotech and Spec Pharma at UBS, and very excited to have United Therapeutics. I have James Edgemond, who is the CFO, and Harry Silvers, who is the IR. Thank you guys so much for joining. Really excited to hear about the story. Maybe, I know a lot of people know your story very well, so you don't really need an introduction as such, but maybe James, if you can hit some highlights from the third quarter earnings that you recently released.

James EdgemondCFO

Yeah. Thank you, Ash. Thanks for hosting Harry and I and United Therapeutics here at your London Healthcare Conference. Harry's going to do a quick Yeah opening remark.

Harry SilversSenior Manager of Investor Relations

Yeah. Ash, thanks for having us. Thanks, everybody in the room and online. Just before James goes, quick disclaimer, we may make some forward-looking statements today, and for any risks and uncertainties associated with those statements, please refer to our filings on Forms 10-K and 10-Q.

James EdgemondCFO

Great. Thank you, Harry. Ash, back to your question. Across the board, we're incredibly proud of what all the Unitherians are performing across the organization. I think just a few highlights, just to break it down, from a commercial standpoint, the base business is performing extremely well. For the third quarter, we reported total revenues that were over $800 million, $833 million. A big part of that was the TYVASO franchise, which reported record revenue of $503 million, $504 million. From a commercial standpoint and base business standpoint, the teams are performing incredibly well, and we see a lot of opportunity for continued growth.

James EdgemondCFO

On the pipeline and the research and development side, as you know, there's a lot of activity that's happening just in terms of across-the-board clinical development to be able to find the right therapies and the right delivery devices to really serve and support the patients, and we're very proud to do that. As you know, looking ahead to 2027, there's some significant activity for us, including the FDA did accept our sNDA to use nebulized TYVASO in IPF, and the clinical trial results were really powerful and should have a clear benefit if approved for the patients. In addition, the NDA for ralinepag in PAH was accepted, and we have a PDUFA date mid-next year to serve and support those patients, which could potentially be the only once-a-day oral therapy for PAH.

James EdgemondCFO

We actually announced too that in the third and fourth quarter of 2027, our TETON clinical trial for PPF, so progressive pulmonary fibrosis, we're going to unblind as well. Really big events happening next year, a lot of clinical development as well. I think coming after that and thinking about the results we've had, we've made some great capital allocation decisions where we have a share repurchase going on right now. The board authorized us for another $2 billion, and we actually used some of our capital to buy down a royalty from Pfizer associated with ralinepag. It should demonstrate, and we had a lot of conviction in that business. Across the board, Ash, a lot of things going on, incredibly proud, and just setting up for Q4 and a 2027 very active year as well.

Ash VermaSMID Biotech and Spec Pharma Analyst

Wonderful. That's great. I think the third quarter revenue was a big positive surprise for us as well. I think just looking at TYVASO, I know there is a few different positives that have played out for you recently. I'm just trying to understand the step-up of growth that we saw in 3Q. Is there a particular driver? We had the sales force expansion recently in beginning of summer, I guess. Is that driving it, or is it coming from PAH, PH-ILD? Just help us understand what are the key drivers of this type of growth?

James EdgemondCFO

Yeah, it's a good question, and we've had that quite a bit. When we exited Q2, what Michael had talked about was the sales teams were seeing a lot of referrals and starts. The messaging was working, the base business was working, and you saw that pull through into Q3 revenue. You mentioned the sales force expansion. Kind of in the July, August timeframe, we talked about expanding the sales force ultimately to move into idiopathic pulmonary fibrosis if that sNDA is approved. But in the meantime, those sales teams have actually been engaged in both deepening the relationships with physicians, focusing on the messaging in terms of diagnosis, use of TYVASO in PAH and PH-ILD. And so those additional sales teams are actually helping us broaden that awareness of the disease state.

James EdgemondCFO

I think what you'll find is the core business is working well, that messaging was working, and you'll start to see the new sales team's impact more looking at Q4 and then looking into 2027. But it just goes to show you when Michael talked about looking at the messaging and really honing in on those relationships and talking about diagnosis really was working, and you saw that coming out of Q2 into Q3, and looking forward to that continuing going forward.

Ash VermaSMID Biotech and Spec Pharma Analyst

Yeah, I think it's fascinating to see that, especially I think that you made more of a commentary on coming out of Q2 that the referrals were at a record pace. Are you seeing that because of the sales force expansion that the referrals are getting a good boost going into Q4?

James EdgemondCFO

Yeah. It's a good question because if you refer back to what Michael talked about coming out of Q3, in the month of October, there was over 1,000 referrals across our commercial portfolio, which was the highest referrals in a single month ever. So with that momentum that you saw in Q3, coming out of Q2, you saw in Q3, October was a very large month for referrals. So that should give a good indication that this momentum is continuing and those sales teams are having an impact, and potentially a larger impact going forward.

Ash VermaSMID Biotech and Spec Pharma Analyst

Yeah. I think one of the questions that I always get from investors is that, is there any off-label IPF that is driving this? Just anything that you can say on that.

James EdgemondCFO

There certainly could be, but we certainly- Yeah don't market to it, and it would be hard for us to get visibility into that because it's not reimbursable specifically for IPF.

James EdgemondCFO

Right. Could there be? Sure, because a physician can certainly write what they deem to be the best therapy for patients.

James EdgemondCFO

But visibility-wise, we wouldn't necessarily get visibility on the reimbursement side.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day